drugset / Trial / NCT03965728

Study to Investigate Safety, Tolerability, Pharmacokinetics, and Drug-drug Interaction of Multiple Oral Doses of BAY1830839 in Healthy Male Participants

NCT03965728

Phase 1 Completed 67 enrolled Bayer
RandomizedSequentialDouble-blindBasic science

Summary

The aim of this study is to investigate safety, tolerability and pharmacokinetics of increasing repeated oral doses of BAY1830839 in healthy male participants including the investigation of any potential drug-drug interactions of BAY1830839 with midazolam and methotrexate. In addition, the effects of BAY180839 on exploratory pharmacodynamics biomarkers in healthy participants will be investigated.

Timeline

Start
2019-06-05
Primary completion
2022-01-21
Completion
2022-05-11

Drugs

EvaluationDrugModalityDoseRoute
Subject BAY1830839 Unknown Oral
Subject Methotrexate Small molecule Oral
Subject Midazolam Small molecule Oral

Indications

No indication recorded.